Camber Capital Management LP

13F Filings History

Latest 13F report
Q3 2024 - Nov 14, 2024
Value $
$2.57B
Signature - Title
Stephen DuBois - Managing Member
Location
Boston, MA
Summary
This page shows a list of all the recent 13F filings made by Camber Capital Management LP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Camber Capital Management LP reported 32 stock holdings with total value $2.57B as of Q3 2024. Top holdings included ZBH, MDT, BAX, VTRS, and GMED.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q3 2024 32 $2.57B +$459M -$628M -$170M ZBH, MDT, BAX, VTRS, GMED 13F-HR 11/14/2024, 09:41 AM
Q2 2024 35 $2.59B +$479M -$608M -$129M ZBH, BAX, MDT, UHS, GMED 13F-HR 8/14/2024, 09:28 AM
Q1 2024 34 $2.86B +$314M -$608M -$294M ZBH, UHS, BAX, THC, VTRS 13F-HR 5/15/2024, 08:48 AM
Q4 2023 36 $2.86B +$445M -$623M -$179M UHS, THC, ZBH, VTRS, BAX 13F-HR 2/14/2024, 08:18 AM
Q3 2023 39 $2.79B +$438M -$378M +$60.3M UHS, THC, ZBH, VTRS, SNY 13F-HR 11/14/2023, 08:56 AM
Q2 2023 38 $3.07B +$271M -$357M -$86.2M UHS, THC, VTRS, SNY, WBA 13F-HR 8/14/2023, 09:26 AM
Q1 2023 40 $2.93B +$387M -$481M -$94.4M SNY, UHS, THC, WBA, VTRS 13F-HR 5/15/2023, 09:06 AM
Q4 2022 38 $2.86B +$425M -$775M -$350M SNY, UHS, VTRS, THC, WBA 13F-HR 2/14/2023, 09:01 AM
Q3 2022 42 $2.99B +$983M -$247M +$736M SNY, VTRS, UHS, SRPT, THC 13F-HR 11/14/2022, 09:37 AM
Q2 2022 40 $2.3B +$476M -$653M -$177M VTRS, SNY, ZBH, SRPT, BMRN 13F-HR 8/15/2022, 08:55 AM
Q1 2022 37 $2.76B +$768M -$487M +$282M VTRS, UHS, SNY, ZBH, GILD 13F-HR 5/16/2022, 08:39 AM
Q4 2021 36 $2.59B +$587M -$597M -$10M VTRS, UHS, MRK, SNY, WBA 13F-HR 2/14/2022, 09:33 AM
Q3 2021 34 $2.69B +$615M -$375M +$240M UHS, WBA, THC, VTRS, SNY 13F-HR 11/15/2021, 09:03 AM
Q2 2021 30 $2.55B +$541M -$678M -$138M THC, WBA, VTRS, HCA, BKD 13F-HR 8/16/2021, 08:52 AM
Q1 2021 31 $2.52B +$595M -$656M -$61.7M CHNG, WBA, UHS, VTRS, THC 13F-HR 5/17/2021, 08:49 AM
Q4 2020 28 $2.43B +$682M -$481M +$201M CHNG, VTRS, UHS, ALXN, HCA 13F-HR 2/16/2021, 08:33 AM
Q3 2020 35 $1.9B +$448M -$287M +$161M CHNG, MYL, ALXN, PRGO, UHS 13F-HR/A 11/16/2020, 04:51 PM
Q3 2020 35 $1.9B +$447M -$287M +$160M CHNG, MYL, ALXN, PRGO, UHS 13F-HR 11/16/2020, 08:39 AM
Q2 2020 30 $1.75B +$439M -$598M -$159M CHNG, MYL, ALXN, ALKS, PRGO 13F-HR 8/14/2020, 08:25 AM
Q1 2020 29 $1.67B +$775M -$669M +$106M ALXN, CHNG, MYL, GSK, UHS 13F-HR 5/15/2020, 08:52 AM
Q4 2019 28 $1.93B +$281M -$461M -$180M AGN, MYL, BIIB, GILD, THC 13F-HR 2/14/2020, 09:22 AM
Q3 2019 32 $1.76B +$453M -$350M +$103M AGN, MYL, PRGO, BKD, DVA 13F-HR 11/14/2019, 09:15 AM
Q2 2019 28 $1.71B +$433M -$369M +$64.3M AGN, MYL, DVA, PRGO, BKD 13F-HR 8/14/2019, 09:16 AM
Q1 2019 27 $1.72B +$432M -$809M -$378M AGN, MYL, PRGO, GBT, BIIB 13F-HR 5/15/2019, 09:45 AM
Q4 2018 32 $1.85B +$623M -$250M +$374M TSRO, MYL, AGN, UHS, MCK 13F-HR 2/14/2019, 10:17 AM
Q3 2018 25 $1.76B +$259M -$719M -$460M AGN, HCA, MYL, TSRO, UHS 13F-HR 11/14/2018, 09:55 AM
Q2 2018 30 $2.14B +$418M -$395M +$22.6M AGN, HCA, BIIB, GHDX, TSRO 13F-HR 8/14/2018, 09:23 AM
Q1 2018 32 $2.04B +$765M -$473M +$292M SHPG, NKTR, AGN, BIIB, HCA 13F-HR 5/15/2018, 08:48 AM
Q4 2017 31 $1.53B +$537M -$387M +$150M NKTR, HCA, MYL, AGN, UHS 13F-HR 2/14/2018, 10:22 AM
Q3 2017 22 $1.2B +$360M -$807M -$447M NKTR, THC, MYL, PRGO, GHDX 13F-HR 11/14/2017, 11:21 AM
Q2 2017 31 $1.64B +$272M -$468M -$196M TEVA, MYL, GILD, NKTR, AGN 13F-HR 8/14/2017, 11:18 AM
Q1 2017 30 $1.69B +$217M -$376M -$159M TEVA, MYL, GILD, NKTR, AGN 13F-HR 5/15/2017, 11:17 AM
Q4 2016 34 $1.73B +$558M -$309M +$249M TEVA, MYL, AGN, GILD, PRGO Restatement 3/16/2017, 09:19 AM
Q3 2016 33 $1.62B +$292M -$498M -$206M TEVA, MYL, PRGO, GILD, ENDPQ 13F-HR 11/14/2016, 11:20 AM
Q2 2016 44 $1.72B +$616M -$514M +$102M TEVA, MYL, ENDPQ, CSII, MDCO 13F-HR 8/12/2016, 03:43 PM
Q1 2016 45 $1.61B +$592M -$213M +$378M TEVA, MYL, MDCO, BKD, NUVA 13F-HR 5/13/2016, 04:00 PM
Q4 2015 40 $1.36B +$387M -$318M +$69.6M TEVA, GHDX, MDCO, LIVN, AZN 13F-HR 2/12/2016, 08:17 AM
Q3 2015 43 $1.17B +$285M -$173M +$112M TEVA, MDCO, AZN, CYBX, MYL 13F-HR 11/13/2015, 10:37 AM
Q2 2015 39 $1.24B +$384M -$287M +$97.3M TEVA, AZN, MASI, MDCO, ESRX 13F-HR 8/14/2015, 10:07 AM
Q1 2015 36 $1.18B +$282M -$388M -$107M TEVA, MASI, MDCO, GHDX, ESRX 13F-HR 5/15/2015, 11:09 AM
Q4 2014 38 $1.2B +$334M -$272M +$62M TEVA, MASI, GSK, GHDX, CNMD Restatement 5/13/2015, 11:50 AM
Q3 2014 35 $991M +$343M -$498M -$155M TEVA, MYL, MASI, GHDX, GSK 13F-HR 11/14/2014, 10:32 AM
Q2 2014 39 $1.21B +$335M -$218M +$117M TEVA, V107SC, DGX, CYH, CNMD 13F-HR 8/14/2014, 10:03 AM
Q1 2014 38 $1.04B +$316M -$370M -$53.5M TEVA, V107SC, THC, DGX, CNMD 13F-HR 5/15/2014, 10:28 AM
Q4 2013 35 $1.04B $0 $0 TEVA, MYL, V107SC, HCA, CNMD 13F-HR 2/14/2014, 07:55 AM